Eyewire News: The Podcast

Outlook Therapeutics takes a major step forward in its plan to gain approval for wet AMD drug Lytenava; the first commercial FLIGHT procedures using the ViaLuxe Laser System are performed in Europe; and Oculus introduces a new AI-assisted tool designed to help clinicians evaluate MGD using meibography images. Learn more about your ad choices. Visit megaphone.fm/adchoices

The FDA approves wireless pressure-modulating goggles for at-home glaucoma treatment; Bausch + Lomb launches a new PreserVision AREDS eye vitamin formation; and an Executive Strategic Advisor discusses the regulation environment for communication in eye care.  Learn more about your ad choices. Visit megaphone.fm/adchoices

Leading ophthalmologists join us to discusses the hottest topics in the posterior segment treatment landscape.  Learn more about your ad choices. Visit megaphone.fm/adchoices

Bayer expands ophthalmology pipeline with acquisiton of Perfuse Therapeutics; Viridian announces new phase 3 data for its investigational subcutaneous injection for chronic thyroid eye disease; and Steven Dell, MD discusses the impact of declining reimbursement could on ophthalmic practices. Learn more about your ad choices. Visit megaphone.fm/adchoices

Ophthalmic executives discuss strategies to scale and grow in today’s economic and regulatory environments.  Learn more about your ad choices. Visit megaphone.fm/adchoices

Glaukos commercially launches its topical drug therapy for keratoconus; BVI’s next-generation phaco-vitrectomy surgical system receives CE Mark; and the ASCRS Executive Director recaps the 2nd annual Sightline meeting.  Learn more about your ad choices. Visit megaphone.fm/adchoices

Eyewire reports on new products and breaking news live from the American Society of Cataract and Refractive Surgery meeting in Washington DC.  Learn more about your ad choices. Visit megaphone.fm/adchoices

A major recall is announced for several store-brand OTC eye drops; the FDA extends dosing intervals for Eylea HD in patients with Wet AMD and DME; and Bausch + Lomb launches its second full range of vision IOL in Europe. Learn more about your ad choices. Visit megaphone.fm/adchoices

Pharma giant Biogen announces its intention to acquire Apellis in a multi-billion dollar deal; a recently approved first-of-its-kind presbyopia drop is commercially launched; and Kodiak Sciences releases phase 3 data for its diabetic retinopathy drug candidate. Learn more about your ad choices. Visit megaphone.fm/adchoices

The Executive Director of The American Society of Cataract & Refractive Surgery (ASCRS) previews the upcoming annual meeting and discusses the most pressing issues facing ophthalmology.  Learn more about your ad choices. Visit megaphone.fm/adchoices

Alcon and Lensar provide a major update to their proposed merger; the latest IOL on Johnson & Johnson’s Tecnis platform receives FDA approval; and the FDA issues another CRL to Aldeyra Therapeutics for its investigational dry eye drug reproxalap. Learn more about your ad choices. Visit megaphone.fm/adchoices

The FDA agrees to review a presbyopia drop designed to modulate pupil dynamics; a new endocapsular device receives clearance in Europe; and Rayner makes an acquisition to expands its cataract surgery portfolio.  Learn more about your ad choices. Visit megaphone.fm/adchoices

Zeiss releases a software app that aims to address longstanding challenges in ophthalmic care; Oertli launches its new surgical platform, the OS 4 Up, in Europe; and Harrow introduces direct-to-prescriber cash-pay kits for ophthalmic branded medications. Learn more about your ad choices. Visit megaphone.fm/adchoices

Ocular Therapeutix releases its long-awaited SOL-1 phase 3 data for wet AMD drug candidate Axpaxli; Nordic Pharma expands the availability of its novel dry eye therapy Lacrifill; and Alcon launches the only multifocal toric contact lens featuring Water Gradient Technology. Learn more about your ad choices. Visit megaphone.fm/adchoices

New research reveals that a popular diabetes treatment may lower the risk of AMD progression; a study examines the performance of large language models on specialty ophthalmology examinations; and a new doctor-led alliance that aims to support private practice optometrists has officially launched.  Learn more about your ad choices. Visit megaphone.fm/adchoices

The FDA approves the first dual-agent eye drop for presbyopia; Rayner launches a personalized, AI-powered patient education platform; and new study examines the link between sleep positioning and eye pressure.  Learn more about your ad choices. Visit megaphone.fm/adchoices

The FDA approves a key label supplement for Glaukos’ iDoseTR; Nidek announces the European launch of a new open-field refraction system; and there have been several leadership changes announced during the first month of 2026. Learn more about your ad choices. Visit megaphone.fm/adchoices

Rayner launches a new phaco system in the US; Eylea 8 mg is approved for a third indication in Europe; and Nanodropper announces a consolidation plan to expand its offerings under a new name.  Learn more about your ad choices. Visit megaphone.fm/adchoices

New research may provide hope for patients with a rare vision-threatening condition; the first daily disposable soft contact lens using EDOF technology for presbyopia is cleared in the US; and there several advancements made in the clinical development of treatment candidates for retinal diseases. Learn more about your ad choices. Visit megaphone.fm/adchoices

Shareholders vote on Alcon’s blockbuster acquisition proposal for Staar Surgical; the FDA responds to Outlook’s latest BLA submission for wet AMD drug Lytenava; and the FDA approves an interchangeable biosimilar to Lucentis.  Learn more about your ad choices. Visit megaphone.fm/adchoices

Highlights from the last 6 months of 2025 include advancements of emerging technologies in glaucoma, the first pharmacologic treatment for myopia in Europe, the expansion of labels for anti-VEGF treatments, and the release of the DEWS III report exploring the diagnosis and management of dry eye disease.  Learn more about your ad choices. Visit megaphone.fm/adchoices

There were several advancements made during the first 6 months of 2025, including the first FDA approval for neurodegenerative disease MacTel; the approval of a first-of-its-kind drug for dry eye disease; advancements in premium IOLs; the approval of an excimer laser platform, and the launch of a new presbyopia drop. Learn more about your ad choices. Visit megaphone.fm/adchoices

Aldeyra provides an update on the timing of its dry eye disease treatment candidate reproxalap; Ocular Therapeutix pursues an accelerated NDA pathway for wet AMD therapy Axpaxli; and companies with late-stage drug candidates announce FDA submission plans.  Learn more about your ad choices. Visit megaphone.fm/adchoices

Companies with plans to commercialize glaucoma technologies in the US reach clinical milestones; Haag-Streit announces the global launch of a new Indirect ROP Laser Module; and EyeYon Medical gets approval to initiate a US clinical study of its EndoArt corneal implant.  Learn more about your ad choices. Visit megaphone.fm/adchoices

Eylea HD gains FDA approval for a new indication and dosing schedule; Lucentis biosimilar Byooviz receives a key approval in Europe; and Belite Bio announces topline results from its global phase 3 trial evaluating its drug candidate for Stargardt disease.  Learn more about your ad choices. Visit megaphone.fm/adchoices

Several new technologies are emerging that aim to transform the way glaucoma is treated and managed. Many of these technologies are now available to patients outside of the United States, with the goal of expanding availability to the US and beyond.  Learn more about your ad choices. Visit megaphone.fm/adchoices

Bausch + Lomb outlines a  strategic path to innovation and growth at its Investor Day; Apellis reports new 5-year data examining Syfovre and GA progression; and two global organizations for restoring sight merge.  Learn more about your ad choices. Visit megaphone.fm/adchoices

Sydnexis receives another regulatory approval for its childhood myopia eye drop; Eli Lilly makes two major investments in ophthalmology; and Nanoscope reports new long-term data for its intravitreal optogenetic therapy for RP. Learn more about your ad choices. Visit megaphone.fm/adchoices

Leaders of several ophthalmic companies provide updates on their pipeline and new products in this special edition of Eyewire News the Podcast. Learn more about your ad choices. Visit megaphone.fm/adchoices

Leaders of several ophthalmic companies provide updates on their pipeline and new products in this special edition of Eyewire News the Podcast. Learn more about your ad choices. Visit megaphone.fm/adchoices

EyewireTV reports on new products and breaking news live from thee American Academy of Ophthalmology meeting in Orlando. Learn more about your ad choices. Visit megaphone.fm/adchoices

Uday Devgan, MD, shares his experience performing the world’s first robotic cataract surgery; Konan Medical receives CE Mark for its objectiveFIELD Analyzer perimetry device; and Biotech Healthcare launches a new full visual range EDOF IOL.  Learn more about your ad choices. Visit megaphone.fm/adchoices

A first-of-its-kind presbyopia eye drop is now commercially available; Lumibird introduces ICL Guru Integration on its ultrasound platform; and the makers of gene therapy candidates for retinal diseases provide clinical updates. Learn more about your ad choices. Visit megaphone.fm/adchoices

Industry executives discuss future innovations and breakthroughs that are poised to reshape the future of ophthalmic care.  Learn more about your ad choices. Visit megaphone.fm/adchoices

Industry executives discuss future innovations and breakthroughs that are poised to reshape the future of ophthalmic care.  Learn more about your ad choices. Visit megaphone.fm/adchoices

EyewireTV reports on new products and breaking news live from the ESCRS Congress in Copenhagen.  Learn more about your ad choices. Visit megaphone.fm/adchoices

A proposal by the Trump Administration calls for cuts to the National Institutes of Health and consolidation of the federal government’s 27 institutes into just eight. This includes folding the National Eye Institute into a new broader institute on neuroscience and brain research. Ophthalmic leaders discuss what the vision care advocacy community is doing to combat proposed cuts to the National Eye Institute.  Learn more about your ad choices. Visit megaphone.fm/adchoices

Several companies with treatment candidates for retinal diseases provide clinical updates; Nicox releases new phase 3 data for its investigational glaucoma eye drop; the first patient is implanted with Ocumetics’ novel accommodating lens; and ASCRS provides details for its second annual Business of Refractive Cataract Surgery Summit. Learn more about your ad choices. Visit megaphone.fm/adchoices

Ciliatech obtains CE certification for the Intercil Uveal Spacer surgical implant; Zeiss receives CE mark for a new device that uses AI to automate OCT assessment; and the FDA extends the target action dates for two Eylea HD submissions. Learn more about your ad choices. Visit megaphone.fm/adchoices

Leaders from the Tear Film and Ocular Surface Society discuss the biggest takeaways from the recently released TFOS DEWS III report. Learn more about your ad choices. Visit megaphone.fm/adchoices

Charles Wykoff, MD, PhD, shares his experience performing the first commercial case for a patient with MacTel; VSY Biotechnology launches its Enova Hydrophobic IOLs with a new preloaded delivery system; and an app is launched that syncs AI directly to leading OCT devices. Learn more about your ad choices. Visit megaphone.fm/adchoices

Alcon makes a major acquisition to expand its refractive portfolio; the CEO of Lenz Therapeutics joins us to discuss the FDA approval of a new presbyopia drop; and the optical industry braces for major changes as new reciprocal tariffs are set to begin this week.   Learn more about your ad choices. Visit megaphone.fm/adchoices

Alcon launches its recently approved dry eye drug Tryptyr; a potential $1 billion deal is made to advance extended-release therapies for eye diseases; and two companies with late-stage AMD drug candidates complete phase 3 enrollment. Learn more about your ad choices. Visit megaphone.fm/adchoices

Harrow enters a deal to expand it biosimilar pharma portfolio; the first gene-agnostic therapy to restore vision in RP patients advances; and Aldeyra provides an update on its dry eye drug candidate reproxalap. Learn more about your ad choices. Visit megaphone.fm/adchoices

Leading ophthalmologists share summaries of their presentations live from thee AECOS Summer Symposium.     Learn more about your ad choices. Visit megaphone.fm/adchoices

Alcon makes a major acquisition to bolster is vitreoretinal surgery portfolio; the European Commission (EC) approves Eylea 8 mg for extended treatment intervals; and Eric Donnenfeld, MD, discusses the business of myopia management. Learn more about your ad choices. Visit megaphone.fm/adchoices

Glaukos receives European Union certification for several of its MIGS technologies; Opus Genetics and Viatris present phase 3 results for their investigational presbyopia eye drop; and J&J launches the first and only daily disposable contact lens for people with both astigmatism and presbyopia.  Learn more about your ad choices. Visit megaphone.fm/adchoices

The leaders of the Holland Foundation provide an update on the progress of the foundation and its mission to restore sight for patients with Severe Ocular Surface Disease. Learn more about your ad choices. Visit megaphone.fm/adchoices

The Tear Film and Ocular Surface Society publishes the third installment of the TFOS DEWS report; J&J launches the Tecnis Odyssey presbyopia-correcting IOL in Europe, the Middle East, and Canada; and Harrow acquires the exclusive US commercial rights to postoperative inflammation and pain drug Byqlovi. Learn more about your ad choices. Visit megaphone.fm/adchoices

The first pharmaceutical treatment for myopia is approved in Europe; the FDA sets a target action date for a first-of-its-kind presbyopia drop; and John Berdahl, MD, discusses the reimbursement landscape in ophthalmology.  Learn more about your ad choices. Visit megaphone.fm/adchoices